The vaccine research and development competition created by the COVID-19 epidemic has made 2020 a new era of vaccines.
html COVID-19 vaccines with more than 0 different technical routes actually completed animal tests and some human clinical trials in less than one year, just like Cambrian Biological Big Explosion , and were approved for emergency use. In less than half a year, more than 2 billion doses of COVID-19 vaccine were received worldwide. At present, the vaccine has excellent effect and safety, and there are no major adverse reactions worth worrying about. The speed of the development and application of this vaccine is definitely unprecedented in human history, but I dare not say it is the last one. With this rapid progress, the next time we face a new infectious disease, we may use the vaccine faster.Against this background, China is becoming a vaccine powerhouse from a vaccine powerhouse. China is the country that has adopted the most technical routes (5) in the world to develop the COVID-19 vaccine, and is also the country that has the most technical routes (3) applied in the actual large-scale vaccination process. It is also the country that has the highest vaccination efficiency and the most vaccination doses. As of yesterday, China has received more than 1.1 billion doses in total.
In addition to COVID-19 vaccines, China has a number of traditional vaccines being developed or are waiting to be launched. These vaccines will tie the vaccine list of developed countries and break the monopoly of traditional vaccine giants.
pneumonia 13-valent combination vaccine is a very important vaccine that breaks the monopoly situation. China has launched a pneumonia 13-valent combination vaccine in 2020, breaking the monopoly of American companies in this field. This year, China will have another pneumonia 13-valent combination vaccine to be launched, forming full competition in the market and bringing more choices to parents of children.
Streptococcus pneumoniae mainly causes pneumococcal diseases, including meningitis, bacteremia and bacteremia pneumonia, otitis media , sinusitis and nonbacteremia pneumonia.
Pneumococcal is a easily transmitted bacteria, and its transmission pathway is mainly droplet transmission.
Pneumococcal carriers can discharge droplets from their mouths or noses by coughing, sneezing, and speaking, and transmit bacteria to healthy people; public places where air is not circulating and crowded, such as stations, kindergartens, nurseries, etc. may become places of infection.
colonization and harm of pneumococcal in the human body
pneumococcal can also be colonized in the human nasopharynx, and autologous infection can occur when the body's resistance decreases.
WHO estimates that 1.6 million people die from pneumococcal infections worldwide every year, of which 460,000 are infants and young children. About 2 million people in my country are infected with pneumococcal infection every year, of which 30,000 children die prematurely.
Because infants and young children are the main hosts of pneumococcal bacteria, they are under 2 years old and have the highest incidence of invasive pneumococcal diseases (IPD) in children, with the highest incidence rate at 6-11 months.
According to statistics, the carrier rate of pneumococcal in nasopharyngeal children in mainland China is 21.7%.
The most effective means to solve the harm of pneumococcal diseases: "Timely vaccination of pneumococcal vaccine".
The World Health Organization recommends that countries around the world should include pneumonia-bound vaccines in their own children’s immunization programs. Especially in countries with high child mortality rates, the introduction of pneumonia multivalent binding vaccines should be regarded as a high priority project in the national immunization program.
pneumococcal mainly harms infants
my country introduced the pneumonia 7-valent binding vaccine from Wyeth in the United States in 2008 (Peer). In 2015, it withdrew from the domestic market due to its import license expiration;
At the end of 2016, the State Food and Drug Administration approved the pneumonia 13-valent binding vaccine from Pfizer (Peer 1 3) It is launched in the mainland;
In 2020, the State Food and Drug Administration approved the 13-valent binding vaccine of pneumonia in Watson, Yunnan (Wo Anxin 13) to be launched;
In 2021, another domestic pneumonia 13-valent binding vaccine has completed registration and is about to be approved for marketing. The vaccine was independently developed by Beijing Minhai Biotechnology, a wholly-owned subsidiary of Kangtai Biotechnology, and is the world's first dual-vector pneumonia 13-valent binding vaccine (Virin Feibao).
Weimin Feibao renderings
dual-vector pneumonia 13-valent binding vaccine, which uses two vector protein to bind pneumococcal capsular polysaccharides. It is different from the single-vector pneumococcal polysaccharide binding vaccine, which can prevent the same carrier protein from competing for helper T cells and exert inhibitory effect on the polysaccharide immune response.
Phase III clinical trial data show that the antibody positive rate and geometric mean titer of 13 serotypes of pneumococcal were not inferior to that of Pfizer in the control group. At the same time, data show that the vaccine has good safety.
Weimin Feibao is a safe and effective vaccine for preventing pneumococcal diseases in infants and young children.
According to the public information of the National Drug Review Center, the first dual-carrier pneumonia 13-valent combination vaccine independently developed by Minhai Bio has undergone the final administrative approval stage and is about to be launched.
The launch of this vaccine fills the gap in the domestic pneumonia 13-valent combination vaccine field, and will become a powerful weapon to prevent pneumococcal diseases in infants and young children, bringing good news to babies and parents.
